In vitro nano‑emodin–associated exosome‑mediated aPDT against Acinetobacter baumannii Authors: Samane Teymouri, Hadiseh Mohammadpour, Maryam Pourhajibagher, Abbas Bahador Published: 2026 ABSTRACT AbstractBiofilm-forming Acinetobacter baumannii, particularly multidrug-resistant (MDR) strains, present major challenges in burn wound treatment. This study evaluated the antibacterial and antibiofilm efficacy of exosomes associated with nano-emodin (NE-Exos) combined with antimicrobial photodynamic therapy (aPDT) against A. baumannii. Antibacterial and antibiofilm activities were evaluated against the standard strain (ATCC 19606) and clinical isolates of A. baumannii, including MDR, extensively drug-resistant (XDR), and non-MDR/non-XDR strains. Minimum inhibitory and bactericidal concentrations (MIC, MBC), biofilm-inhibitory and eradication concentrations (MBIC, MBEC), drug release, hemolysis, and expression of biofilm-associated genes (abaI, bap) were evaluated. Nano-emodin and NE-Exos showed inhibitory and antibacterial activities with MIC and MBC values ranging from 15 to 39 μg/mL and 30 to 156 μg/mL, respectively. NE-Exos showed better antibiofilm efficacy compared to nano-emodin alone, especially in MDR isolates. The release of nano-emodin from NE-Exos reached 30.73% nano-emodin release at pH 5.5 after 300 min, compared to 27.56% and 23.76% at pH 7.4 and 8.5, respectively, and was associated with minimal hemolysis (0.015%). Furthermore, NE‑Exos combined with aPDT significantly downregulated the biofilm‑associated genes abaI and bap, with reductions of up to 10.96‑fold and 5.33‑fold, respectively (p < 0.001). Exosomes may have contributed to the observed antimicrobial effects, although their role appears to be as a carrier for nano‑emodin. These findings support NE‑Exos combined with aPDT as a promising in vitro strategy against A. baumannii biofilms; however, the lack of direct quantification of nano‑emodin encapsulation should be considered a study limitation.Keywords: Exosomes, Nano-emodin, Antimicrobial photodynamic therapy, Biofilms, Acinetobacter baumannii Introduction Acinetobacter baumannii, an opportunistic pathogen, is a major cause of nosocomial infections worldwide. Its strong ability to form biofilms and high levels of antibiotic resistance are important factors in its persistence and prevalence in healthcare-associated infections (Nocera et al. 2021). Recent global reports indicate A. baumannii strains exhibiting multidrug (MDR), extensively drug-resistant (XDR), and pan-drug–resistant (PDR) phenotypes, demonstrating resistance to almost all clinically available antibiotics (Cavallo et al. 2023; Teymouri et al. 2024). Certain surface proteins of A. baumannii, including outer membrane protein A (OmpA), β-lactamase PER-1 (blaPER-1), and biofilm-associated protein (Bap), play important roles in biofilm formation and promote bacterial adhesion to both human epithelial cells and abiotic surfaces. Among these, Bap is essential for the initial attachment and subsequent development of A. baumannii biofilms (Brossard et al. 2012). The abaI gene encodes an autoinducer synthase responsible for the production of N-acyl homoserine lactone (AHL) signaling molecules. Mutations in abaI lead to a significant reduction in biofilm formation (Niu et al. 2008). Previous studies have shown that contaminating bacteria, including A. baumannii, can form multispecies biofilms in burn wounds. Such biofilm formation complicates the management of infections and may lead to treatment failure in certain cases (Firoozeh et al. 2023). The current management of burn wound infections typically involves a combination of wound debridement and the administration of systemic or topical antimicrobial agents. Although antibiotics remain the primary therapeutic option, their excessive use can contribute to the development of antimicrobial resistance (Pourhajibagher et al. 2021). Regarding antibiotic resistance, developing novel strategies to combat the emergence of antimicrobial-resistant strains and to prevent microbial biofilm formation is crucial. Antimicrobial photodynamic therapy (aPDT) represents a promising alternative approach for treating superficial infections in targeted areas. In aPDT, photosensitizers (PS) are activated from a lower-energy state to a higher-energy state. The antimicrobial activity of aPDT arises primarily through two distinct photochemical pathways- Type I and Type II- which proceed from the triplet excited state. In the Type I mechanism, the triplet PS engages in electron- or hydrogen- transfer reactions with nearby biomolecules or endogenous cellular substrates. This leads to the generation of radical species such as PS*−, PS*+, which subsequently react with dissolved oxygen to form a spectrum of reactive oxygen species (ROS), including superoxide anion (O2*−), hydroxyl radicals (*OH), and hydrogen peroxide (H2O2). These species inflict oxidative damage on microbial membranes, proteins, and nucleic acids. The Type II pathway involves a direct energy- transfer process from the triplet PS to ground- state molecular oxygen (3O2), producing singlet oxygen (1O2), a highly reactive, electronically excited form of oxygen. This pathway becomes predominant when oxygen availability is sufficient. Singlet oxygen reacts with a broad range of cellular targets, particularly unsaturated lipids and certain amino acid residues, leading to membrane destabilization and rapid cell inactivation (Austin et al. 2025). The relative contribution of Type I versus Type II pathways depends on multiple factors, including the intrinsic photophysical properties of the PS, local oxygen availability, and the biochemical microenvironment of the microbial cells (Martins Antunes de Melo et al. 2021). These mechanisms highlight the crucial role of PSs in aPDT. Consequently, the development of effective PS carriers has attracted attention in the field. Currently, numerous studies are investigating the application of exogenous nanocarriers to improve the formulation and performance of PSs. Exosomes, a distinct class of extracellular vesicles, have been increasingly investigated as potential drug delivery platforms and serve as natural mediators of intercellular communication (Dao et al. 2022). Exosomes demonstrate therapeutic potential, specially in enhancing the delivery of agents that combat bacterial infections. While their role in wound healing through promoting angiogenesis and collagen synthesis is recognized their capacity for targeted drug carrier is also important (Yang et al. 2021, 2024). Exosomes hold promise for increasing the carrier of therapeutic agents like emodin. By potentially assisting in the delivery of emodin, exosomes may help overcome limitations such as low bioavailability and potential safety concerns, thereby enhancing the concentration of the drug at the site of infection and enhancing its antibacterial activity (Pourhajibagher and Bahador. 2024). The efficacy of aPDT in reducing microbial load and bacterial virulence has been demonstrated in numerous studies, showing minimal invasiveness and limited tissue damage. However, enhancing the overall effectiveness of this approach requires further exploration of alternative PSs. The success of aPDT largely depends on several factors, including the use of an effective carrier system for the PS and sufficient local access to the site of infection (Mesquita et al. 2018). Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) is a natural anthraquinone derivative extracted from plants such as Polygonum cuspidatum and Rheum palmatum (Pourhajibagher et al. 2022). Previous studies have highlighted the broad range of beneficial properties of emodin, including its antiviral, antibacterial, antibiofilm, antiulcerogenic, hepatoprotective, immunosuppressive, anticancer, and antiinflammatory activities. Emodin has shown significant antimicrobial activity, indicating its potential as a promising agent for the management and control of bacterial biofilms (Janeczko et al. 2017; Teymouri et al. 2025; Dong et al. 2016). The binding capacity and biofilm-forming ability of A. baumannii contribute to the pathogenesis of various infections, particularly burn wound infections. The bap and abaI genes are key regulators involved in cell adhesion, pili formation, biofilm development, and antibiotic resistance in A. baumannii. Suppressing or downregulating the expression of these genes can consequently reduce biofilm formation, thereby improving the efficacy of therapeutic interventions in burn wound infections. Therefore, this study aims to synthesize and conduct a biological assessment of exosomes associated with nano-emodin (NE-Exos) as a delivery system for aPDT against A. baumannii biofilms. The experimental work encompassed nanoparticle characterization, antibacterial and antibiofilm activities drug release, hemolysis assay, and expression of biofilm-associated genes (abaI, bap) were evaluated. Materials and methods Culture conditions of bacterial strains To evaluate the antimicrobial effects of nano-emodin-associated exosomes (NE-Exos)-mediated aPDT, nine clinical isolates of A. baumannii from burn wound infections, obtained in previous studies, were utilized. These included three non-MDR/non-XDR isolates, three MDR isolates, and three XDR isolates (Bahador et al. 2014). Additionally, a standard strain of A. baumannii (American Type Culture Collection, ATCC 19606) was obtained from the Iranian Biological Resource Center, Tehran, Iran. Both the standard and clinical isolates of A. baumannii were inoculated in Brain Heart Infusion (BHI) broth (Merck, Germany), chosen for its nutrient-rich composition that promotes biofilm formation, and incubated in a shaking incubator at 37 °C under aerobic conditions with an agitation speed of 6.0 × g overnight. Cultures were grown to a concentration of 1.5 × 108 colony-forming units (CFU)/mL during the logarithmic growth phase. The turbidity of the cultures was standardized to the 0.5 McFarland standard, and the optical density (OD) was measured at 600 nm, ranging from 0.08 to 0.13. Culture of human mesenchymal stem cells for exosome extraction Human mesenchymal stem cells (hMSCs, IBRC C11474, Iran) were cultured for the extraction of exosomes. Cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM-F12; HiMedia Labs, India) supplemented with 10% exosome-depleted fetal bovine serum (FBS), 100 U/mL penicillin, 100 μg/mL streptomycin, 100 μg/mL amphotericin B, and 2 mM L-glutamine to ensure optimal growth. Cells were seeded into culture flasks and incubated at 37 °C in a humidified atmosphere containing 5% CO2. After 24–48 h, hMSCs adhered firmly to the flask surface. The culture medium was then removed, and the cell monolayer was gently washed with pre-warmed phosphate-buffered saline (PBS, pH 7.4) at 37 °C to eliminate residual medium and non-adherent cells. Primary cultures were maintained for 12–15 days, with the medium replaced every three days. During each replacement, approximately two-thirds of the medium was carefully removed and replenished with an equal volume of fresh complete medium to support sustained cell growth and viability. Extraction of exosomes Exosomes were isolated using the EXOCIB kit (Cib Biotech, Iran, Cat. No. 3603–450) according to the manufacturer’s instructions. Briefly, hMSCs were centrifuged at 1509 × g for 20 min to remove cells and debris. The supernatant was then mixed with exosome precipitation solution (Reagent A) and incubated overnight at 4 °C. Following incubation, the mixture was centrifuged at 1509 × g for 40 min to pellet the exosomes. The resulting exosome pellet was resuspended in PBS (pH 7.4) and stored at –70 °C until further use. Characterization of exosomes Exosome morphology was examined by TEM (Zeiss EM10C, Germany) using samples prepared through standard fixation, dehydration, and resin embedding procedures: purified exosomes were fixed in 2% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) at 4 °C for 1 h, washed three times with the same buffer, post‑fixed in 2% osmium tetroxide at 4 °C for 1 h, dehydrated through a graded ethanol series (50–100%), infiltrated with low‑viscosity resin, polymerized at 65 °C for 24 h, sectioned into ultrathin 60 nm slices, and stained with 2% uranyl acetate followed by lead citrate before imaging at 80 kV. The particle size distribution was assessed by DLS using a Zetasizer Nano‑ZS (Malvern Instruments, UK); frozen exosome preparations were thawed at room temperature, diluted to 200 µL in PBS (pH 7.4) using 50 µL of stock exosomes, and analyzed under standard instrument settings for hydrodynamic diameter measurement. The protein concentration of the isolated exosomes was determined using the Bradford assay. Briefly, 5 μL of the exosome sample was mixed with 500 μL of Bradford reagent (Sigma-Aldrich, Germany) and incubated in the dark for 10 min to allow complete binding of Coomassie Brilliant Blue dye to the protein. Upon binding, the dye changed color from brown to blue. The absorbance of the solution was measured at 595 nm using a UV–Vis spectrophotometer. Protein concentrations were calculated using a standard curve prepared from known concentrations of bovine serum albumin (BSA) (Sigma-Aldrich, Steinheim, Germany) (Dash et al. 2021). For exosome surface marker analysis, exosomes were labeled with CD63 antibodies. This labeling process, potentially combined with natural aggregation, resulted in particles large enough to be detected by the FACSCalibur flow cytometer, enabling the assessment of CD63 expression on these enriched exosome populations. Preparation of nano-emodin Nano‑emodin was prepared using a modified version of the Ding et al. method (Ding et al. 2018), in which we optimized solvent ratios, PBS compatibility, and sonication conditions to improve emodin dispersion and control particle size. Briefly, emodin was first dissolved in PBS (1 mg/mL, pH 7.4) to ensure complete hydration of the aqueous phase, then 2 mg lecithin was added to 2 mL of this solution. Separately, 2 mg cholesterol was fully dissolved in 5 mL ether and slowly introduced to the aqueous mixture to facilitate uniform contact between the lipid and aqueous phases. The mixture was gently stirred at 6.7 × g for 10 min at room temperature, after which the organic solvent was removed by rotary vacuum evaporation at 28 °C and 200 mmHg to address both the volatility of ether and the PBS solubility limitations. The resulting emulsion was subjected to pulse‑probe sonication (JY92‑2D, 20 kHz, 300 W) for 15 min in an ice bath using 5 s on/ 5 s off cycles to control heating and ensure nanoscale dispersion. The suspension was centrifuged at 2683 × g for 10 min, and the supernatant was passed through a 0.22 µm filter to remove aggregates while retaining the nanoparticle fraction, yielding the final nano‑emodin preparation used for subsequent analyses. Characterization of nano-emodin The surface morphology of nano-emodin was examined using scanning electron microscopy (SEM; SERON AIS-2100, South Korea) at an accelerating voltage of 15 kV. TEM (ZEISS EM10C, Germany) was subsequently performed at 100 kV to examine the morphological characteristics. Particle size, size distribution, and zeta potential of nano‑emodin (100 µg/mL in distilled water) were measured using a Malvern Zetasizer Nano‑ZS (Version 6.01, Malvern Instruments, UK). Samples were sonicated for 5 min in a water bath to ensure uniform dispersion, and 1 mL of the suspension was loaded into a disposable DLS cuvette for analysis. Particle size and distribution were determined by dynamic light scattering at 25 °C using the instrument’s standard 173° backscattering angle. Zeta potential was measured in a dedicated zeta cuvette using laser Doppler electrophoresis under the same temperature and default measurement conditions of the instrument. Energy-dispersive X-ray spectroscopy (EDS) mapping was used to determine the elemental composition of nano-emodin. Fourier-transform infrared (FTIR) analysis was performed using two spectrophotometers across a wavelength range of 500–4000 cm−1 (ZnSe 45° crystal, PerkinElmer Inc., USA). Preparation of nano‑emodin–associated exosomes Nano‑emodin was associated with exosomes using a probe‑sonication method. A nano‑emodin stock was prepared by dissolving 5 mg of nano‑emodin in 0.5 mL PBS (pH 7.4) and mixed with isolated exosomes at a 1:9 mass ratio (1 mg nano‑emodin to 9 mg exosomes), yielding a final nano‑emodin concentration of 1 mg per 10 mg of exosome suspension. The mixture was subjected to probe sonication at 25% amplitude for seven cycles, each consisting of 30 s on and 30 s off, with 2‑min cooling intervals in an ice bath to prevent thermal damage. After sonication, the suspension was incubated for 1 h at room temperature to allow membrane recovery, and unencapsulated nano‑emodin or aggregated vesicles were removed by centrifugation at 1075 × g for 10 min at 4 °C, followed by three PBS washes under the same conditions. The pellet containing nano‑emodin–associated exosomes was carefully collected, resuspended in cold PBS, and homogenized gently to ensure uniform dispersion (Haney et al. 2015). The formation of NE-Exos was subsequently indicated using TEM. In vitro release of nano-emodin from NE-Exos In vitro release of nano‑emodin from NE‑Exos was evaluated under different pH conditions by quantifying the amount of free nano‑emodin in the release medium. For each condition, 15 mg of lyophilized NE‑Exos powder was resuspended in 10 mL PBS at pH 5.5, 7.2, or 8.5 and incubated at 37 ± 0.5 °C with gentle shaking. At predetermined time points (0, 30, 120, 210 and 300 min), 4 mL of the suspension was withdrawn and processed through a 100‑kDa ultrafiltration unit (Amicon Ultra, Millipore) by centrifugation at 2683 × g for 15 min. This ultrafiltration step effectively retained intact NE‑Exos in the upper reservoir while allowing only free nano‑emodin to pass into the filtrate, ensuring that nano‑emodin associated with exosomes did not interfere with spectrophotometric measurements. The filtrate was collected, and an equal volume of fresh PBS was added to the release vessel to maintain constant volume and physiological conditions throughout the experiment. The concentration of released nano‑emodin in each filtrate was quantified by UV‑Vis spectrophotometry at 430 nm. Standard solutions of nano‑emodin (2–8000 µg/mL) were prepared, their OD recorded, and a calibration curve established. The nano‑emodin concentrations of the filtrate samples were determined from this standard curve. The release of nano-emodin at each pH and time point was calculated using the following Eq. (1) (Mailafiya et al. 2019): The initial nano‑emodin concentration in the NE‑Exos preparation was determined to be 10,000 µg/mL. Hemolysis assay A hemolysis assay was performed to evaluate the biocompatibility of nano‑emodin–associated exosomes (NE‑Exos). Sheep red blood cells (RBCs) (Baharafshan, Iran) were used for this test. Defibrinated sheep blood was centrifuged at 800 × g for 5 min at 37 °C to pellet the RBCs, and the cells were washed three times with 10 mL PBS (pH 7.4), each time centrifuging at 800 × g for 5 min to remove plasma and residual proteins. After the final wash, the RBCs were resuspended in PBS to prepare a 3% hematocrit suspension. For the hemolysis experiment, 400 µL of a 10,000 µg/mL NE‑Exos solution (prepared from lyophilized NE‑Exos powder dissolved in PBS, pH 7.4) was added to 600 µL of the 3% RBC suspension, yielding a final reaction volume of 1 mL. The mixtures were incubated at 37 °C for 2 h and subsequently centrifuged at 2683 × g for 5 min to collect the supernatant. The released hemoglobin in the supernatant was quantified by measuring the absorbance at 540 nm using a UV–Vis spectrophotometer. RBCs incubated in PBS (pH 7.4) served as the negative control (0% hemolysis), while RBCs incubated in distilled water served as the positive control (100% hemolysis). The percentage of hemolysis was calculated using the following Eq. (2) (Gao et al. 2018): Evaluation of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) The MIC and MBC of the treatment groups were determined according to the Clinical and Laboratory Standards Institute (CLSI) M100 2022 guidelines (CLSI 2022). Per CLSI definitions, the MIC is the lowest concentration of an antimicrobial agent that prevents visible microbial growth. The Sub-MIC was defined as the highest concentration of nano-emodin, NE-Exos, or exosomes at which visible bacterial growth was detected in the wells of microplates after incubation. Bacterial growth was assessed by turbidity compared to the growth control. For the broth microdilution assay, Brain Heart Infusion (BHI) broth was used as the culture medium. Two-fold serial dilutions were prepared for nano-emodin (3.9–8,000 µg/mL), NE-Exos (4.88–10,000 µg/mL), and exosomes (0.38–780.42 µg/mL). All concentrations (µg/mL) refer to the amount of lyophilized nano‑emodin, NE‑Exos, or exosome powder dissolved in solution. A 96‑well microtiter plate was prepared by dispensing 100 µL of BHI broth into each well, followed by 100 µL of each test agent. The bacterial inoculum was prepared by adjusting overnight cultures to a 0.5 McFarland standard (1.5 × 108 CFU/mL), then diluting 1:300 in the wells to achieve a final inoculum of 5 × 105 CFU/mL. The microplate included a negative control (medium alone) and a positive control (medium with bacteria). After incubation at 37 °C for 24 h, the turbidity of the wells was assessed to determine bacterial growth. The MBC is defined as the lowest concentration of an antimicrobial agent that kills bacteria, corresponding to the highest dilution or lowest concentration at which no bacterial growth is observed on agar plates. To determine MBC values, 2 μL of the contents from microplate wells showing no turbidity in the MIC assay were inoculated onto BHI agar plates. The plates were incubated at 37 °C for 24 h (Rodríguez-Melcón et al. 2021). Evaluation of biofilm biomass reduction (minimum biofilm eradication concentration, MBEC‐based assessment) The MBEC is defined as the lowest concentration of an antimicrobial agent required to eradicate/degrade mature bacterial biofilms. Sub-MBEC was defined as the highest concentration of nano-emodin, NE-Exos, or exosomes at which bacterial biofilm formation was detected by crystal violet staining and OD measurement. To establish biofilms, 100 μL of bacterial suspension in BHI broth (final concentration 1.5 × 106 CFU/mL) was added to each well of a 96-well microplate. The microplate was incubated at 37 °C for 24 h to allow the formation of mature biofilms for MBEC determination. After biofilm development, the medium was removed, and planktonic cells were eliminated by washing the wells three times with PBS (pH 7.4). The biofilm-embedded bacterial cells were treated with 100 μL of nano-emodin, NE-Exos, or exosomes at concentrations of 1.95–4,000 μg/mL, 2.4–5,000 μg/mL, and 0.38–780.42 μg/mL, respectively. Afterwards, the microplates were incubated for 24 h at 37 °C. Next, planktonic cells were removed, and the wells were washed three times with PBS (pH 7.4). The adherent biofilms were fixed with 95% ethanol for 15 min at 25 °C. After the ethanol was removed, the microplates were air-dried. A colorimetric assay using crystal violet was employed to evaluate biofilm-killing activity. Each well was then stained with 1% crystal violet for 20 min at 25 °C. After removing the dye, the wells were washed three times with PBS (pH 7.4). Finally, 100 μL of 33% acetic acid was added to each well, and biofilm biomass was quantified by measuring the OD at 570 nm using a microplate reader (Thermo Fisher Scientific, USA) (Jaffar et al. 2016). The OD values were normalized to blank wells containing sterile culture medium and staining reagents without bacteria, and results were expressed as a percentage of the untreated control group. The effectiveness of the different treatment groups in eradicating biofilms was determined by calculating the percentage of biofilm eradication using the following Eq. (3): Evaluation of minimum biofilm inhibitory concentration (MBIC) The MBIC was determined using a 6-h assay. Briefly, 100 μL of bacterial suspension (1.5 × 106 CFU/mL) was added to each well of a 96-well microplate and incubated at 37 °C for 24 h to allow initial biofilm formation. Then the wells were treated with nano-emodin, NE-Exos, or exosomes at concentrations described in the MBEC evaluation. The microplates were incubated in the dark at 37 °C for 6 h. After incubation, non-adherent and residual planktonic cells were removed by washing the wells three times with PBS (pH 7.4). The subsequent steps were performed as described in the MBEC assay using crystal violet staining and OD measurement to assess biofilm formation. The MBIC was defined as the lowest concentration of each compound that inhibited biofilm formation and resulted in biofilm biomass comparable to the negative control. The sub-MBIC was defined as the highest concentration of an antimicrobial agent at which residual biofilm formation was still detectable. The untreated bacterial suspension was used as the positive control to demonstrate maximum biofilm formation. The wells containing only sterile culture medium without bacterial inoculation were used as the negative controls (Macia et al. 2014; Tavafi 2021). The percentage of biofilm inhibition was calculated using the following Eq. (4): All MIC, MBC, MBEC, and MBIC assays were performed under dark conditions to determine the intrinsic antimicrobial activity of the compounds. Continuous illumination during the long incubation periods would not reflect controlled aPDT irradiation; therefore, the photodynamic effect was evaluated separately in dedicated aPDT experiments. Study design To evaluate the antimicrobial susceptibility of A. baumannii ATCC 19606 to NE-Exos, the experimental groups were arranged as follows: Nano-emodin (compound only) Nano-emodin (compound only) NE-Exos (compound only) NE-Exos (compound only) Exosome (compound only) Exosome (compound only) Light only Light only Nano-emodin + aPDT)light) Nano-emodin + aPDT)light) NE-Exos + aPDT)light) NE-Exos + aPDT)light) Exosome + aPDT)light) Exosome + aPDT)light) Negative control (untreated bacteria) Negative control (untreated bacteria) aPDT was applied using a blue laser diode (ASHA, Iran) with a wavelength of 405 ± 20 nm, an output intensity of 150 mW/cm2. The device was operated at 4.2 V and 0.34 A for 60 s. A 96-well microplate was positioned upright at a fixed distance of 10 cm from the laser probe, with each well exposed to an illuminated area of 0.33 cm2. Assessment of the effects of blue laser light on A. baumannii To evaluate the impact of blue laser exposure on bacterial viability, 100 μL of A. baumannii suspension (final concentration 1.5 × 105 CFU/mL) was added into flat‑bottom microplate wells. A 405‑nm blue laser (beam spot diameter: 1 cm; illuminated area: 0.785 cm2; output intensity: 0.15 W/cm2) was applied for 1, 2, 3, 4, or 5 min. Based on these parameters, the corresponding light doses were 9, 18, 27, 36, and 45 J/cm2, respectively. A non‑irradiated bacterial suspension under identical conditions (0‑min exposure) served as the negative control. Following irradiation, 10 μL of each well was spread onto BHI agar (Merck, Germany) plates. Plates were incubated at 37 °C for 24 h, and CFU/mL values were determined according to the Miles method (Miles et al. 1938). The exposure duration that produced a statistically significant reduction in CFU counts compared with the non‑irradiated control was defined as the sub‑lethal dose for subsequent experiments. Evaluation of antimicrobial activity To assess the effect of aPDT on the viability of A. baumannii ATCC 19606 and clinical isolates in the planktonic phase, 100 μL of bacterial suspension (1.5 × 106 CFU/mL) was added to each well of a 96-well microplate. Subsequently, 100 μL of nano-emodin, NE-Exos, or exosomes at sub-MIC concentrations (groups a–c) was added to the bacterial suspension. The mixtures were incubated at room temperature (24 ± 3 °C) for 5 min. For group d, the A. baumannii ATCC 19606 suspension was exposed to a 405 nm blue laser for 5 min. In groups e–g, 100 μL of nano-emodin, NE-Exos, or exosomes at sub-MIC concentrations was added to the bacterial suspension, followed by exposure to the light source at the specified wavelength after a 5 min incubation. Group h, which received no treatment, served as the control. Following treatment, bacterial suspensions were subjected to tenfold serial dilutions, and 10 μL of each dilution was plated onto BHI agar. Plates were incubated at 37 °C for 24 h, and bacterial viability was determined by counting CFU/mL. Assessment of metabolic activity by XTT reduction assay The metabolic activity of A. baumannii was evaluated using the XTT reduction assay. Briefly, sodium 3-[1-(phenylamino-carbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate (XTT; Roche Applied Science, Indianapolis, IN, USA, Cat. No. 11 465 015 001) was employed to measure bacterial metabolic activity, resulting in the formation of a soluble formazan product proportional to the number of metabolically active cells (Sherwani et al. 2015). After biofilm formation by the standard A. baumannii strain (ATCC 19606), all treatment groups were exposed to the experimental conditions described in the “Evaluation of Antimicrobial Activity” section, following the methodology of Coraça-Hubér et al. (Coraça‐Hubér et al. 2012). Immediately after completing the treatments, without any additional incubation period, the wells were gently washed with PBS (pH 7.4), and 100 μL of freshly prepared XTT solution was added to each well. The XTT mixture consisted of the XTT labeling reagent and the electron‑coupling reagent at a 50:1 ratio (5.0 mL: 0.1 mL). The microplates were incubated in the dark at 37 °C for 3 h, and the absorbance of the resulting formazan was measured at 490 nm using a microplate reader. To account for background absorbance, two types of controls were included: (i) a reagent blank, consisting of wells containing XTT solution without bacteria, for background subtraction; and (ii) a growth control, consisting of untreated biofilms treated with XTT, to establish the 100% metabolic activity reference. Metabolic activity was calculated according to Eq. (5). Analysis of gene expression via quantitative real-time PCR (qRT-PCR) The effect of sub-MBIC levels of nano-emodin, NE-Exos, and MIC levels of exosomes combined with a sublethal dose of blue light on the expression of abaI and bap genes was evaluated in A. baumannii ATCC 19606 and clinical isolates. Total RNA was extracted from bacterial pellets using 1 mL of cold RNX-Plus reagent (SinaClon, Iran). The samples were vortexed for 10 s and incubated at room temperature for 5 min. Subsequently, 200 μL of chloroform was added, the mixture was gently inverted, incubated on ice for 5 min, and centrifuged at 24,077 × g for 15 min at 4 °C. The top aqueous layer was transferred to a new microtube and mixed with an equal volume of isopropanol, followed by incubation on ice for 20 min and centrifugation under the same conditions. The resulting RNA pellet was washed with 1 mL of 75% ethanol and centrifuged at 4,777 × g for 10 min at 4 °C. The supernatant was discarded, and the RNA pellet was air-dried briefly before being resuspended in 20 μL of diethyl pyrocarbonate (DEPC)-treated water and incubated at 25 °C for 5 min. The quality and quantity of total RNA were assessed using a NanoDrop® ND-1000 spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA, USA) by measuring absorbance at 230, 260, and 280 nm and calculating the 260/280 and 260/230 ratios. The 260/280 ratio indicates contamination by proteins, and the 260/230 ratio indicates contamination by salts or organic compounds. To eliminate any residual genomic DNA, the RNA samples were treated with RNase-free DNase I (Thermo Fisher Scientific GmbH, Bremen, Germany). Complementary DNA (cDNA) was then synthesized using a cDNA synthesis kit (Zist Virayesh, Iran, Cat. No. ZV06010050). qRT‑PCR analyses were performed using three biological replicates, each quantified in three technical replicates, to ensure reproducibility and statistical reliability. qRT-PCR was performed on a LightCycler 96 system (Roche, Germany) using SYBR Green qPCR Master Mix (2X; Zist Virayesh, Iran, Cat. No. ZV06010050). Each 20 µL reaction mixture contained 10 µL of 2X SYBR Green Master Mix, 0.5 µL of forward primer (10 µM), 0.5 µL of reverse primer (10 µM), 2 µL of cDNA template, and 7 µL of RNase-free water. The qRT-PCR cycling conditions were as follows: initial denaturation at 95 °C for 10 min, followed by 40 cycles of denaturation at 95 °C for 15 s, annealing at 60 °C for 30 s, and extension at 72 °C for 30 s. A melting curve analysis was performed from 65 °C to 95 °C at a ramp rate of 0.1 °C/s to confirm primer specificity. The expression levels of abaI and bap genes were quantified using the 2−ΔΔCt method and normalized to the 16S rRNA gene as an internal control (Schmittgen et al. 2008). 16S rRNA was selected as the reference gene because it exhibited stable expression across all treatment conditions in preliminary assessments, consistent with its widespread use as a housekeeping gene in A. baumannii. The Ct values of the target genes (abaI and bap) were normalized to the Ct value of the reference gene (16S rRNA) to obtain ΔCt (ΔCt = Cttarget − Ctreference). Then, ΔΔCt was calculated by subtracting the ΔCt of the untreated control group from the ΔCt of the treated samples (ΔΔCt = ΔCttreated − ΔCtcontrol). The relative fold change in gene expression was then calculated as 2−ΔΔCt. Primer sequences were designed using Primer-BLAST (NCBI, Bethesda, MD, USA). The primer sequences utilized in the present study are summarized in Table 1, and their specificity was confirmed by melting curve analysis. Table 1Primer sequences used in the present studyGenePrimers (5′ to 3′)Product size (bp)abaITGCCAGACTACTACCCACCAGATGACACAGCCTGACTGCT165bapTCAGGCAACTGCGGATATGGCATCTGCCGAAGGATCTGCT16116S rRNAACGCGAAGAACCTTACCTGGCCCAACATCTCACGACACGA121abaI, acyl-homoserine-lactone synthase involved in quorum sensing and biofilm regulation; bap, biofilm-associated protein involved in adhesion and biofilm stability; 16S rRNA, housekeeping gene used for normalization of gene expression; bp, base pair Primer sequences used in the present study TGCCAGACTACTACCCACCA GATGACACAGCCTGACTGCT TCAGGCAACTGCGGATATGG CATCTGCCGAAGGATCTGCT ACGCGAAGAACCTTACCTGG CCCAACATCTCACGACACGA abaI, acyl-homoserine-lactone synthase involved in quorum sensing and biofilm regulation; bap, biofilm-associated protein involved in adhesion and biofilm stability; 16S rRNA, housekeeping gene used for normalization of gene expression; bp, base pair Statistical analyses All experiments were performed in triplicate, and data are presented as mean ± standard deviation (SD). Statistical analyses were conducted using GraphPad Prism software, version 10.5 (GraphPad Software, San Diego, CA, USA). Comparisons between treatment and control groups were performed using one-way analysis of variance (ANOVA), and p-values < 0.05 were considered statistically significant. Results Confirmation of exosome isolation TEM images of the exosomes (Fig. 1A) revealed a predominantly spherical morphology with smooth surfaces. The TEM analysis indicated that the average diameter of the exosomes was less than 200 nm. As expected for nanoscale vesicles, TEM provided the dry‑state core diameter, whereas DLS measured the hydrodynamic diameter, which also reflects the surrounding solvation layer and any small degree of particle interaction. Characterization of isolated exosomes from mesenchymal stem cells: A transmission electron microscopy (TEM) image showing exosome morphology (scale bar = 200 nm, magnification = 27.800 KX), B size distribution measured by dynamic light scattering (DLS), C protein concentration determined by Bradford assay, and D flow cytometric analysis of the exosomal marker CD63 confirming exosome identity DLS measurements (Fig. 1B) showed a particle size distribution ranging from 50 to 350 nm, with a mean diameter of 156 nm. The presence of particle sizes up to 350 nm is consistent with hydrodynamic broadening and a small proportion of transiently aggregated vesicles, which commonly appear in exosome preparations and do not contradict the TEM observations. The main peak detected by both techniques falls within the characteristic nanoscale range of exosomes, supporting the identity of the isolated population. The histogram in Fig. 1B represents the frequency of particle-size events reconstructed from the intensity-weighted DLS distribution. Moreover, the protein concentration of the exosomes was quantified using a standard calibration curve generated from serial dilutions of BSA at known concentrations, in combination with the Bradford reagent. The total exosomal protein concentration was calculated to be 780.423 μg/mL (Fig. 1C). Additionally, CD63, a specific exosomal surface marker, was successfully detected in the isolated exosomes (Fig. 1D). Confirmation of nano-emodin synthesis SEM analysis (Fig. 2A) showed that nano‑emodin formed irregular nanoscale particles, although the presence of larger clusters suggested partial aggregation during sample preparation. Similarly, TEM images (Fig. 2B) revealed electron‑dense nanoparticles; however, some particles appeared aggregated, which is consistent with the moderate surface charge and drying‑related clustering. Characterization of nano-emodin. A Scanning electron microscope (SEM) image of nano-emodin (scale bar = 10 µm, magnification = 1.00 KX), B transmission electron microscopy (TEM) image of nano-emodin (scale bar = 250 nm, magnification = 21.560 KX), C size distribution measured by dynamic light scattering (DLS), D Zeta potential analysis, E energy-dispersive X-ray spectroscopy (EDS) spectrum, F Fourier transform infrared spectroscopy (FTIR) spectrum of nano-emodin DLS analysis (Fig. 2C) indicated that the particle size distribution ranged from 65 to 102 nm, with an average particle diameter of 76.9 nm. The zeta potential analysis of nano-emodin (Fig. 2D) showed a surface charge of 20.8 mV. This charge suggests only moderate colloidal stability. Colloidal systems typically require values above approximately ± 30 mV to maintain strong electrostatic repulsion; therefore, the moderate charge observed here may contribute to the aggregation seen in the electron microscopy images. EDS mapping (Fig. 2E) indicated that nano-emodin consists of 84.2% carbon and 15.8% oxygen by weight. The FTIR analysis (Fig. 2F) exhibited characteristic emodin functional groups, confirming successful nano‑emodin formation. FTIR spectrum exhibited peaks at 607.50, 723.85, 769.87, 862.66, and 941.60 cm−1, corresponding to C–H stretching vibrations and C–C bond vibrations. This spectrum exhibited peaks at 2855.27 cm−1 and 2921.67 cm−1, corresponding to CH2–CH3 symmetric stretching and CH3 asymmetric stretching, respectively. The peaks at 1734.96 cm−1 (C=O stretching) and 3432.23 cm−1 (β‑hydroxyl stretching) are consistent with the quinone and phenolic groups of emodin. Additionally, the peaks at 1392.39 cm−1 and 1462.45 cm−1 are attributed to O–H bending and C=C stretching vibrations within the benzene rings. Slight peak broadening compared with free crystalline emodin indicates molecular interactions occurring during nanoformulation, further supporting the successful synthesis of nano‑emodin. Morphological characterization of NE‑Exos TEM micrographs (Fig. 3) showed the presence of spherical, membrane‑bound vesicle‑like structures with diameters predominantly below 200 nm, which is consistent with the typical morphology of exosomes. The vesicles appeared well‑distributed without obvious aggregation, indicating preservation of vesicular integrity after the nano‑emodin association procedure. Transmission electron microscopy (TEM) image of nano-emodin-associated exosomes (scale bar = 200 nm, magnification = 27.800 KX) In vitro nano-emodin release The release of nano-emodin from NE-Exos (Fig. 4) was evaluated at three different pH values (5.5, 7.4, and 8.5) over 300 min. A time‑dependent increase in drug release was observed, with the highest release occurring at acidic pH. After 30 min, 10.4% of nano-emodin was released at pH 5.5, compared with 8.5% and 6.3% at pH 7.4 and 8.5, respectively. By 120 min, the release reached 18.16% at pH 5.5, while it was 13.93% at pH 7.4 and 11.26% at pH 8.5. At 300 min, the formulation released 30.73% of nano-emodin at pH 5.5, while release at pH 7.4 and 8.5 reached 27.56% and 23.76%, respectively. In vitro release of nano-emodin from nano-emodin-associated exosomes at different pH values Hemolysis assay The percentage of hemolysis was determined by measuring hemoglobin levels in the supernatant. As shown in Fig. 5, NE-Exos did not induce detectable hemolysis, suggesting that it does not disrupt membrane integrity or form pores in RBCs. At a final concentration of 10,000 µg/mL, the hemolysis percentage of NE-Exos was 0.015%. Hemolysis assay of nano-emodin-associated exosomes MIC, MBC, MBEC, and MBIC of nano-emodin, exosomes, and NE-Exos The MIC, MBC, MBEC, and MBIC values of nano-emodin, NE-Exos, and exosomes for A. baumannii ATCC 19606 and clinical isolates are presented in Table 2. For the ATCC 19606 strain, the MIC values of nano-emodin, NE-Exos, and exosomes were 15, 39, and 97.55 µg/mL, respectively, while the corresponding MBC values were 30, 78, and 195.10 µg/mL. Both nano-emodin and NE-Exos demonstrated an MBIC of 125 µg/mL and an MBEC of 500 µg/mL, whereas exosomes did not exhibit inhibitory or eradication activity against biofilms. Table 2MIC, MBC, MBIC, and MBEC values of nano-emodin, NE-Exos, and exosomes against Acinetobacter baumannii isolatesIsolatesExperimentsNano-emodin(μg/mL)NE-Exos(μg/mL)Exosomes(μg/mL)ATCC 19606MIC153997.55MBC3078195.10MBIC125 ± 0.021125 ± 0.026NoMBEC500 ± 0.012500 ± 0.002NoNon-MDR/non-XDRMIC313997.55MBC6278195.10MBIC500 ± 0.35312 ± 0.0015NoMBEC1000 ± 0.078624 ± 0.065NoMDRMIC1578195.10MBC31156390.21MBIC125 ± 0.051156 ± 0.042NoMBEC250 ± 0.039312 ± 0.074NoXDRMIC1539195.10MBC3178390.21MBIC62 ± 0.04878 ± 0.035NoMBEC250 ± 0.069312 ± 0.051NoData are shown as mean ± SD of three experiments (n = 3). MBIC and MBEC values indicate variability, MIC and MBC are reported as single values. NE-Exos, Nano-emodin-associated exosomes; MIC, Minimum inhibitory concentration; MB, Minimum bactericidal concentration; MBIC, Minimum biofilm inhibitory concentration; MBEC, Minimum biofilm eradication concentration; No, No MBIC or MBEC was detected within the concentration range tested MIC, MBC, MBIC, and MBEC values of nano-emodin, NE-Exos, and exosomes against Acinetobacter baumannii isolates Data are shown as mean ± SD of three experiments (n = 3). MBIC and MBEC values indicate variability, MIC and MBC are reported as single values. NE-Exos, Nano-emodin-associated exosomes; MIC, Minimum inhibitory concentration; MB, Minimum bactericidal concentration; MBIC, Minimum biofilm inhibitory concentration; MBEC, Minimum biofilm eradication concentration; No, No MBIC or MBEC was detected within the concentration range tested For non-MDR/non-XDR isolates, the MIC values of nano-emodin, NE-Exos, and exosomes were 31, 39, and 97.55 µg/mL, respectively, and the MBC values were 62, 78, and 195.10 µg/mL. The MBIC values were 500 µg/mL for nano-emodin and 312 µg/mL for NE-Exos, whereas exosomes did not inhibit biofilm formation. The MBEC values were 1000 µg/mL and 624 µg/mL for nano-emodin and NE-Exos, respectively, with no detectable MBEC for exosomes. For MDR isolates, the MIC values of nano-emodin, NE-Exos, and exosomes were 15, 78, and 195.10 µg/mL, respectively, while the MBC values were 31, 156, and 390.21 µg/mL. The MBIC values were 125 µg/mL for nano-emodin and 156 µg/mL for NE-Exos, and exosomes showed no antibiofilm activity. The MBEC values were 250 µg/mL and 312 µg/mL for nano-emodin and NE-Exos, respectively, whereas exosomes did not demonstrate biofilm eradication. For XDR isolates, the MIC values of nano-emodin, NE-Exos, and exosomes were 15, 39, and 195.10 µg/mL, respectively, and the MBC values were 31, 78, and 390.21 µg/mL. The MBIC values were 62 µg/mL for nano-emodin and 78 µg/mL for NE-Exos, while exosomes showed no inhibitory effect on biofilm formation. The MBEC values for nano-emodin and NE-Exos were 250 µg/mL and 312 µg/mL, respectively, and no MBEC value was detected for exosomes. Although exosomes displayed measurable MIC and MBC values, this activity was only observed at relatively high concentrations and was not accompanied by any MBIC or MBEC effects. This suggests that the detected activity is likely due to nonspecific interactions between lipid-rich vesicles and bacterial membranes at high doses, rather than intrinsic antimicrobial properties. Impact of blue laser light on A. baumannii The viability of A. baumannii was quantified using colony‑forming unit counts (CFU/mL), as shown in Fig. 6. The Y‑axis represents absolute CFU values (× 105), and all percentage reductions reported in the text are derived from these CFU measurements. Exposure to blue laser light for 1, 2, and 3 min (energy doses of 9, 18, and 27 J/cm2, respectively) produced no statistically significant reduction in CFU compared with the control group (p > 0.05). The CFU values decreased only slightly, corresponding to 1.14%, 3.44%, and 9.19% reductions relative to the untreated control. Effect of different durations of blue laser irradiation on the viability of Acinetobacter baumannii. Significant differences compared with the control are indicated as *p < 0.05 and ****p < 0.0001 In contrast, irradiation for 4 and 5 min (36 and 45 J/cm2) resulted in significant reductions in CFU counts. The 4‑min exposure caused a 15.51% decrease (p < 0.05), whereas the 5‑min exposure produced a marked 39.65% reduction (p < 0.0001). Based on these CFU data, 4 min of blue laser illumination was defined as the sublethal irradiation duration. Although 5 min of irradiation produced a stronger antibacterial effect, 4 min (36 J/cm2) was selected for subsequent experiments to ensure a sublethal light dose. This approach allowed us to evaluate the combinational effect of blue laser irradiation with nano‑emodin, exosome, and NE‑Exos without excessive bacterial killing by light alone, thereby enabling a more accurate assessment of photodynamic enhancement. Metabolic activity of A. baumannii The antimetabolite activity of nano-emodin (at sub-MBIC and sub-MBEC concentrations of 62.5 μg/mL and 250 μg/mL, respectively), nano-emodin + aPDT (7.5 μg/mL and 15 μg/mL), NE-Exos (62.5 μg/mL and 250 μg/mL), NE-Exos + aPDT (62.5 μg/mL and 125 μg/mL), exosomes alone (at MIC, 97.55 μg/mL), and exosomes + aPDT (at MIC, 97.55 μg/mL), in combination with a sublethal dose of blue laser irradiation against A. baumannii, was evaluated using the XTT reduction assay. Our results (Fig. 7) indicate that the nano-emodin group at sub-MBEC exhibited a significant reduction in metabolic activity to approximately 77% (p < 0.05), reflecting partial inhibition of bacterial metabolism. Treatment with nano-emodin combined with aPDT led to a more notable reduction in metabolic activity, reaching approximately 69% at sub-MBEC and 81% at sub-MBIC (p < 0.01 and p < 0.05, respectively), suggesting enhanced efficacy when combining aPDT with nano-emodin, particularly at the sub-MBEC concentration. The effect of different treatment groups (nano-emodin alone, nano-emodin + aPDT, Nano-emodin-associated exosomes (NE-Exos), NE-Exos + aPDT at sub-MBEC and sub-MBIC concentrations, as well as exosome alone, exosome + aPDT, and light alone at MIC concentrations) on the metabolic activity of Acinetobacter baumannii. The green curve represents the control sample in each treatment group. Significant differences compared with the control group are indicated as *p < 0.05 and **p < 0.01 The combination of NE-Exos with aPDT further reduced metabolic activity to 80% and 83.5% at sub-MBEC and sub-MBIC, respectively (p < 0.05), representing a significant improvement compared to NE-Exos alone (p > 0.05). Other treatments did not differ significantly from the control group (p > 0.05). Importantly, because the XTT assay reflects metabolic activity rather than direct cell viability, the observed 20–30% reductions indicate partial metabolic inhibition rather than complete antibacterial killing. This observation is in agreement with the results of the CFU, MBIC, and MBEC assays, which demonstrated more substantial reductions in viable bacterial counts and biofilm biomass, indicating that the XTT assay primarily reflects early metabolic inhibition. Expression of biofilm-associated genes qRT-PCR was performed on A. baumannii ATCC 19606 and clinical isolates to assess the expression levels of abaI, bap, and 16S rRNA following aPDT. The melting curves for each primer, shown in Fig. 8, demonstrated a single peak per primer, indicating the amplification of a unique product and confirming the specificity of the primers for these genes. Specificity of primers for A 16S rRNA, B abaI, and C bap genes. The left panels represent the amplification curves of each gene, while the right panels show the corresponding melting curve analyses confirming amplification specificity The expression profiles of abaI and bap were further evaluated following aPDT at sub-MBIC concentrations of NE-Exos. Specifically, the concentrations used were 62.5 μg/mL for the ATCC 19606 group, 156 μg/mL for the non-MDR/non-XDR group, 39 μg/mL for the XDR group, and 78 μg/mL for the MDR group of clinical isolates. Sub-MBIC values were determined for each isolate according to its susceptibility, and gene expression analysis was conducted under strain-specific sub-inhibitory conditions. These analyses allowed comparison of gene expression across different bacterial strains and treatment conditions. As shown in Fig. 9, treatment with nano-emodin combined with aPDT in the ATCC 19606 strain resulted in a significant downregulation of both the abaI gene (1.95-fold decrease, p < 0.05) and the bap gene (2.42-fold decrease, p < 0.01) compared with the untreated control group. The greatest reduction in the expression of these genes was observed in the NE-Exos + aPDT treatment group, with a 3.91-fold decrease in abaI (p < 0.01) and a 3.64-fold decrease in bap (p < 0.001). Effect of different treatment groups on the expression levels of abaI and bap genes in Acinetobacter baumannii. The left panels show the relative expression of the abaI gene, while the right panels show the relative expression of the bap gene. A Standard strain (ATCC 19606), B clinical non-MDR/non-XDR isolates, C MDR isolates, and D XDR isolates. Data are shown as mean ± SD. Significant differences compared with the control group are indicated by *p < 0.05, **p < 0.01, and ***p < 0.001. NE-Exos, Nano-emodin-associated exosomes Among the non-MDR/non-XDR isolates, a similar pattern was observed. The nano-emodin + aPDT (1.99-fold decrease, p < 0.05) and NE-Exos + aPDT (4.33-fold decrease, p < 0.01) treatment groups significantly reduced abaI expression. Likewise, bap expression was markedly suppressed, showing a 2.76-fold decrease (p < 0.05) and a 4.36-fold decrease (p < 0.001), respectively. In the MDR isolates, the NE-Exos + aPDT treatment group showed a significant 10.96-fold reduction in abaI gene expression (p < 0.01). Regarding the bap gene, a significant decrease was also observed, a 2.14-fold reduction in the nano-emodin + aPDT group (p < 0.05) and a 5.33-fold reduction in the NE-Exos + aPDT group (p < 0.001). In the XDR isolates, a significant reduction in gene expression was observed only in the NE-Exos + aPDT treatment group, with a 6.70-fold decrease in abaI and a 3.47-fold decrease in bap (p < 0.05). In all types of isolates, other treatment groups, including nano-emodin alone, exosome alone, light alone, and exosome + aPDT, did not show any statistically significant changes in gene expression. Discussion In this study, nano-emodin was employed as a photosensitizer (PS). Emodin, a naturally occurring compound found in numerous plants, has demonstrated antimicrobial activity against a variety of pathogens. However, its clinical application is limited by low solubility and poor bioavailability. One potential strategy to overcome these limitations is the use of exosomes as drug carrier systems. Exosomes have recently attracted attention as potential therapeutic vehicles due to their capacity to communicate with and transport diverse biological cargoes (Lu et al. 2011). Previous studies have suggested that exosome-based carrier systems may enhance the efficacy of antimicrobial agents, including those used in aPDT (Wu et al. 2017). The nanoscale size of nanoformulations, such as exosomes containing nano-emodin, allows for greater penetration into bacterial biofilms, which are often resistant to conventional antibiotics (Mohanta et al. 2023). Furthermore, exosome-based carriers can improve the solubility, stability, and bioavailability of emodin, provide controlled release, and enhance therapeutic efficacy (Muttiah et al. 2025). In addition, exosomes serve as carriers of antimicrobial agents and play a role in improving burn wound healing, skin regeneration, and aesthetic outcomes (Yang et al. 2023). The present findings do not provide evidence for a strong intrinsic antimicrobial effect of exosomes under our experimental conditions. Exosomes may have served mainly as carriers for nano-emodin, while exosome-only treatments did not show antibacterial effects detectable in the assays used. The present study demonstrates that NE-Exos combined with aPDT effectively disrupt A. baumannii biofilms derived from the standard strain (ATCC 19606) and clinical isolates from burn wounds. The MIC, MBC, MBIC, and MBEC values of nano-emodin against A. baumannii ATCC 19606 were determined to be 15 μg/mL, 30 μg/mL, 125 μg/mL, and 500 μg/mL, respectively. Overall, nano-emodin and NE-Exos exhibited significant antimicrobial and antibiofilm activity against both ATCC 19606 and clinical isolates of A. baumannii, including non-MDR/non-XDR, MDR, and XDR strains. However, in resistant isolates, the exosome-based carrier systems improved antimicrobial performance. The enhanced antibiofilm effect observed with the combination treatment may be due to improved stability, better interaction with the biofilm matrix, or local retention of nano-emodin. The antibiofilm data, as reflected by MBIC and MBEC values, further support the superior efficacy of NE-Exos. Specifically, NE-Exos required lower concentrations to inhibit biofilm formation and eradicate/degrade biofilms compared with nano-emodin alone, whereas exosomes alone showed minimal antibiofilm activity. This effect was greater in MDR isolates, where NE-Exos reduced MBIC and MBEC values compared with nano-emodin alone. In our study, nano‑emodin and NE‑Exos required relatively high concentrations to eradicate mature biofilms of A. baumannii. This finding is consistent with previous reports showing that A. baumannii biofilms display extreme tolerance to antimicrobial agents, often requiring concentrations several‑fold higher than those effective against planktonic cells. Importantly, the intended applications of these formulations are topical, where high local concentrations can be safely achieved. Furthermore, the combination with light activation provides an additional antimicrobial mechanism that may reduce the required concentrations in practical settings. The minimal activity observed with exosomes alone indicates that the observed enhancement is attributable to the encapsulated nano-emodin rather than the carrier itself. These findings are consistent with previous studies showing that nanocarrier or exosome-based carrier systems can improve the efficacy of antimicrobial agents, particularly against biofilm-forming and drug-resistant bacteria. By reducing the concentrations required to inhibit growth and disrupt biofilms, NE-Exos may reduce potential cytotoxicity and improve therapeutic outcomes. In addition, the ability of NE-Exos against MDR and XDR isolates highlights its potential as a broad-spectrum strategy for combating A. baumannii infections. Chukwujekwu et al. (Chukwujekwu et al. 2006) reported that the MIC of emodin was 7.8 × 106μg/mL against Bacillus subtilis and 3.9 × 106 μg/mL against Staphylococcus aureus. In a study conducted by Li et al. (Li et al. 2016), the MIC and MBC values of emodin against Haemophilus parasuis were reported as 32 μg/mL and 64 μg/mL, respectively. In another study, Pourhajibagher et al. (Pourhajibagher et al. 2021) reported that the MIC of nano-emodin for a multi-species bacterial suspension, including Pseudomonas aeruginosa ATCC 27853S, Staphylococcus aureus ATCC 25923, and A. baumannii ATCC, was 0.015 μg/mL. The MBEC was determined to be 0.25 μg/mL, approximately four times higher than the MBIC of 0.062 μg/mL. The study by Pourhajibagher et al. (Pourhajibagher et al. 2022) reported that the MIC of nano-emodin against Streptococcus mutans was 6.2 μg/mL. Moreover, Yang et al. (Yang et al. 2015) and Lu et al. (Lu et al. 2011) found that the MIC was 100 μg/mL against Streptococcus suis and 50 μg/mL against Aeromonas hydrophila, respectively. When comparing our MIC values with those reported in previous studies, several methodological differences may explain the variability. Factors such as differences in strain virulence, culturing conditions, nano‑formulation methods, light parameters, and variations in PS concentrations can all affect MIC outcomes. The clinical isolates used in this study, particularly MDR and XDR strains, may also inherently exhibit higher tolerance levels, which could account for the observed discrepancies. In this study, nano-emodin, as a free drug, exerts its antimicrobial effect primarily through direct interaction with bacterial cells, resulting in a relatively low MIC value (15 μg/mL) due to its rapid bioavailability. In contrast, encapsulation of nano-emodin within exosomes provides enhanced stability and controlled release, which can modulate its antimicrobial efficacy over time. However, this controlled release may lead to a higher apparent MIC (39 μg/mL), as higher concentrations are required to achieve comparable antimicrobial effects. Furthermore, the results indicated that exosomes alone did not affect biofilm formation in any of the tested isolates; consequently, no MBIC or MBEC values could be determined. Yang et al. (Yang et al. 2018) demonstrated that exosomes, serving as carriers of antimicrobial agents, can effectively transport these drugs into cells, thereby enhancing their intracellular antimicrobial activity. The study evaluated the efficacy of linezolid-loaded exosomes against methicillin-resistant Staphylococcus aureus (MRSA)-infected macrophages in a mouse model of MRSA infection. The results indicated that antimicrobial agents formulated with exosomes showed significantly more effective in treating intracellular MRSA infections compared to the administration of free-form antibiotics, such as linezolid. In addition, treatment with serum-derived exosomes significantly increased wound healing in diabetic mice. These exosomes can promote angiogenesis and facilitate fibroblast migration, thereby contributing to tissue repair (Chen et al. 2021). Park et al. (Park et al. 2023) showed exosomes derived from adipose tissue stem cells (ASCEs) improved skin health by reducing redness and wrinkles, enhancing brightness, and promoting a more even skin tone (p = 0.005). According to Qian et al. (Qian et al. 2020), exosomes loaded with silver nanoparticles provided multiple therapeutic benefits in treating Pseudomonas aeruginosa-induced skin lesions in mice. These benefits included promoting collagen formation, enhancing angiogenesis, and exhibiting potent antibacterial activity, leading to a significant reduction in bacterial proliferation. The XTT assay results indicate that the combination of NE-Exos with aPDT exerts a significant inhibitory effect on the metabolic activity of A. baumannii (p < 0.05). Specifically, metabolic activity in sub-MBEC conditions decreased from approximately 77% with nano-emodin alone (p < 0.05) to 69% when combined with aPDT (p < 0.01), indicating an enhanced antibacterial effect of the combined treatment compared to nano-emodin alone. No significant changes were observed in the light-only group (p > 0.05), confirming that light exposure in the absence of PSs is insufficient to inhibit bacterial metabolic activity and highlighting the essential role of the PS in the efficacy of aPDT. Collectively, these findings demonstrate that nano-emodin, particularly when formulated with exosomes and combined with aPDT, can substantially reduce the metabolic activity of A. baumannii (p < 0.05). Although the XTT assay indicated metabolic inhibition, this response alone does not equate to full bactericidal activity and may instead reflect sublethal oxidative stress. Additional assays such as membrane integrity tests or ATP quantification would help clarify the extent of bacterial damage. The photodynamic mechanism underlying nano-emodin activity is primarily ROS-driven. The significant elevation in ROS after treatment suggests that oxidative damage is a major contributor to growth inhibition and biofilm disruption. Moreover, the controlled increase in nano‑emodin release from NE‑Exos over 300 min, with a modest initial rise, indicates sustained drug availability at the infection site, which is particularly important for prolonged antimicrobial and antibiofilm activity against A. baumannii in burn wound infections. The low hemolysis rate (0.015%) indicates a favorable safety profile, which is relevant to clinical applications in burn wounds where tissue compatibility is critical. These results indicate excellent biocompatibility, as the observed hemolysis is well below the standard threshold of 5% (ASTM 2013). In a study by Pumirat et al. (Pumirat et al. 2024), A. baumannii mutants lacking abaI exhibited marked impairments in biofilm formation, motility, and virulence, accompanied by altered antibiotic susceptibility profiles, revealing potential vulnerabilities that could be targeted therapeutically. The reduced abaI expression confirms these functional defects and likely impairs quorum sensing, a mechanism important for biofilm maintenance and bacterial communication. Similarly, suppression of the bap gene, which encodes a biofilm-associated protein important for maintaining biofilm structural integrity and stability in clinical environments, has been reported as a key indicator of reduced biofilm formation and virulence in clinical strains of A. baumannii (Azimi et al. 2025). In another study, Pourhajibagher et al. (Pourhajibagher et al. 2020) demonstrated that treatment with silver sulfadiazine nanoliposomes combined with Curcumin-aPDT (AgSD-NLs@Cur-aPDT) significantly reduced the number of A. baumannii isolates from burn wound infections in both planktonic and biofilm forms, as well as the expression level of the luxI gene (p < 0.05). In animal models, de Vasconcelos Catão et al. (de Vasconcelos Catão et al. 2015) showed that aPDT stimulates collagen production and maturation, processes that are important for burn wound healing (p < 0.001). The present study demonstrates that nano-emodin combined with aPDT exerts a significant inhibitory effect on the expression of abaI and bap genes in A. baumannii, with the strongest inhibitory effects observed when nano-emodin is formulated with exosomes. In the ATCC 19606 strain, treatment with nano-emodin + aPDT significantly downregulated abaI (1.95-fold) and bap (2.42-fold). NE-Exos + aPDT further enhanced this effect, achieving reductions of 3.91-fold and 3.64-fold, respectively. These results suggest that exosome-based formulation may improve the antibacterial performance of nano-emodin, possibly by affecting its local availability and interaction with bacterial biofilms and cell membranes. However, these findings are based on in vitro experiments and should not be interpreted as direct evidence of clinical applicability. A similar trend was observed in non-MDR/non-XDR clinical isolates, where both nano-emodin + aPDT and NE-Exos + aPDT significantly suppressed abaI and bap expression, with exosome-based formulations producing more potent effects. These findings indicate that even in isolates without multidrug resistance, exosome encapsulation enhances the antibiofilm and antivirulence activity of nano-emodin. In MDR isolates, treatment with NE-Exos + aPDT resulted in the most substantial reduction in abaI expression (10.96-fold) and bap expression (5.33-fold), whereas nano-emodin + aPDT produced a moderate decrease in bap (2.14-fold). These results indicate that exosome-based formulations are particularly beneficial in resistant strains, possibly overcoming barriers related to membrane permeability or efflux mechanisms that limit the efficacy of free nano-emodin. Interestingly, in XDR isolates, significant gene suppression was only observed in the NE-Exos + aPDT group (6.70-fold decrease in abaI and 3.47-fold decrease in bap), whereas other treatment groups, including nano-emodin alone, exosomes alone, light alone, and exosome + aPDT, were ineffective. This highlights the potential role of combined treatment and exosome-based formulations in overcoming extreme drug resistance. In this study, abaI and bap were analyzed as representative markers of quorum sensing and biofilm maturation in A. baumannii. Although both genes were down‑regulated by the treatment, other biofilm‑related pathways including adhesion genes (e.g., csuA/B, ompA), and polysaccharide biosynthesis (pgaA–D) may also be affected. Broader gene‑expression profiling will be required to fully clarify these mechanisms in future studies. Overall, the results provide in vitro evidence that NE-Exos combined with aPDT can reduce bacterial growth, inhibit biofilm formation, and suppress key virulence-associated genes in A. baumannii. However, these effects were observed exclusively under controlled laboratory conditions, and the present findings should not be interpreted as direct indicators of clinical efficacy. In addition, the encapsulation efficiency of nano‑emodin was not directly measured in this study, and its association with exosomes was therefore assessed indirectly. Limitation In this study, the effects of NE‑Exos‑mediated aPDT were evaluated only in vitro using the standard A. baumannii strain ATCC 19606 and a limited number of clinical isolates (n = 9), which may reduce the generalizability of the findings. In vivo efficacy and safety assessments were not performed, and co‑culture systems involving bacterial cells and mammalian skin cells (e.g., fibroblasts or keratinocytes) were also not included. Burn wound infections commonly involve polymicrobial communities, which may influence treatment responsiveness. Factors such as proteins, exudates, and tissue debris may further affect the interaction between the photosensitizer and bacteria. Although the morphological characteristics of NE‑Exos were evaluated, confirmation of nano‑emodin association with exosomes remained indirect, as quantitative or molecular analyses were not conducted. Encapsulation efficiency, loading capacity, and long‑term physicochemical stability were not assessed. Comparative techniques such as FTIR analysis or other analytical methods capable of verifying drug incorporation were not performed, limiting definitive confirmation of nano‑emodin interaction with the exosomal membrane. Due to imaging limitations, high‑resolution SEM/TEM images of isolated nanoparticles were not obtainable. Additionally, exosomal markers such as CD9 and CD81 were not analyzed, representing an additional methodological limitation. Conclusion The results of this study demonstrate that NE‑Exos–mediated aPDT can reduce MIC, MBC, MBIC, and MBEC values and thereby inhibit biofilm formation by A. baumannii in vitro. Moreover, the combined use of NE‑Exos and aPDT attenuated the expression of the biofilm‑associated genes abaI and bap in both the standard strain and clinical isolates, including non‑MDR/non‑XDR, MDR, and XDR phenotypes. These findings collectively indicate that NE‑Exos formulations, when used alongside aPDT, may serve as a promising adjunctive strategy for weakening virulence and biofilm‑associated tolerance mechanisms in A. baumannii in vitro conditions. However, as these findings are based only on in vitro experiments, further studies using in vivo models and comprehensive cytotoxicity evaluations in mammalian systems are needed to optimize treatment protocols for burn wound infections and other relevant pathogens. Acknowledgements The authors would like to thank and appreciate the financial support from Tehran University of Medical Sciences and Health Services. Abbreviations Acinetobacter baumannii N-acyl homoserine lactone One-way analysis of variance Antimicrobial photodynamic therapy Adipose tissue stem cells Biofilm-associated protein Brain Heart Infusion β-Lactamase PER-1 Bovine serum albumin Colony-forming units Clinical and Laboratory Standards Institute Dynamic light scattering Dulbecco’s Modified Eagle’s Medium Energy-dispersive X-ray spectroscopy Food and Drug Administration Fetal bovine serum Fourier-transform infrared spectroscopy Human mesenchymal stem cells Minimum bactericidal concentration Minimum biofilm eradication concentration Minimum biofilm inhibitory concentration Multidrug resistance Minimum inhibitory concentration Nano-emodin-associated exosomes Optical density Outer membrane protein A Phosphate-buffered saline Pan-drug-resistant Photosensitizers Quantitative real-time polymerase chain reaction Red blood cells Reactive oxygen species Standard deviation Scanning electron microscopy Transmission electron microscopy Extensively drug-resistant Author contributions Samane Teymouri: Writing—review and editing, Writing—original draft, Software, Methodology, Investigation, Formal analysis. Hadiseh Mohammadpour: Software, Methodology, Formal analysis. Maryam Pourhajibagher: Writing—review and editing, Writing—original draft, Visualization, Supervision, Resources, Project administration, Investigation, Conceptualization. Abbas Bahador: Writing—review and editing, Writing—original draft, Visualization, Supervision, Resources, Project administration, Investigation, Conceptualization. Funding This research was funded by Tehran University of Medical Science and Health Services Grant No. 1402–1–101–66921. Data availability All data generated or analyzed during this study are included in this manuscript. Declarations Ethical approval and consent to participate The study was approved by the Ethics Committee of Tehran University of Medical Sciences (Application No. IR.TUMS.BLC.1401.057). Generative AI in Scientific writing None declared. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Maryam Pourhajibagher, Email: m-pourhajibagher@sina.tums.ac.ir. Abbas Bahador, Email: abahador@sina.tums.ac.ir. References Associated Data Data Availability Statement All data generated or analyzed during this study are included in this manuscript.